M E MARSHALL
Overview
Explore the profile of M E MARSHALL including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
300
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Small E, Meyer M, MARSHALL M, Reyno L, Meyers F, Natale R, et al.
J Clin Oncol
. 2000 Mar;
18(7):1440-50.
PMID: 10735891
Purpose: Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC). A prospective randomized clinical trial was designed to evaluate pain and...
2.
MYERS R, Brown D, Oelschlager D, Waterbor J, MARSHALL M, Srivastava S, et al.
Int J Cancer
. 1996 Oct;
69(5):398-402.
PMID: 8900374
Expression of a truncated or extracellular form (p105erbB-2) of p185erbB-2 has been demonstrated in the sera of breast cancer patients. We examined the levels of p105erbB-2 in the sera of...
3.
MARSHALL M, Wolf M, ORourke M, Barnett T, Crawford E
Cancer Biother Radiopharm
. 1996 Apr;
11(2):119-23.
PMID: 10851528
Based upon prior data suggesting that alpha-interferon possesses chemomodulatory activity, the Southwest Oncology Group conducted a study in which patients with hormone refractory, metastatic (stage D2) adenocarcinoma of the prostate...
4.
MARSHALL M, Wolf M, Crawford E, Weiss G, Ahmann F, Meyers F, et al.
Am J Clin Oncol
. 1995 Oct;
18(5):400-2.
PMID: 7572756
CHIP, a second generation analogue of cisplatin, was subjected to a Phase II trial for the treatment of advanced, hormonally refractory carcinoma of the prostate. Forty-six patients were treated with...
5.
Ebbinghaus S, Herrera G, MARSHALL M
Cancer Biother
. 1995 Jan;
10(3):237-41.
PMID: 8547962
Rhabdoid tumor of the kidney is an uncommon and highly aggressive malignancy usually found in the pediatric age group. This tumor does not respond well to aggressive chemotherapy regimens and...
6.
MARSHALL M, Wolf M, Crawford E, Thompson I, Flanigan R, Balcerzak S, et al.
Cancer Biother
. 1995 Jan;
10(3):205-9.
PMID: 8547959
Alpha-interferon (IFN) has been shown to produce antitumor responses among patients with advanced renal cell carcinoma. While responses have been observed over a range of IFN doses and schedules, significant...
7.
MARSHALL M, Blumenstein B, Crawford E, Thompson I, Craig J, Eisenberger M, et al.
Am J Clin Oncol
. 1994 Dec;
17(6):514-5.
PMID: 7977172
Amonafide (benzisoquinolinedione; NSC 308847) was subjected to a Phase II trial for the treatment of advanced hormone-refractory carcinoma of the prostate. In addition to adequate baseline organ functions, patients were...
8.
Adams D, Cowan C, MARSHALL M, Stark J
Physiol Behav
. 1994 Feb;
55(2):247-54.
PMID: 8153162
Two types of fighting (offense) were compared and contrasted in three experiments on the laboratory rat. In Experiment 1, competitive fighting was obtained in pairs of hungry cagemates by placing...
9.
MARSHALL M, Mohler J, Edmonds K, Williams B, Butler K, Ryles M, et al.
J Cancer Res Clin Oncol
. 1994 Jan;
120 Suppl:S39-42.
PMID: 8132703
Several authors have demonstrated that coumarin (1,2-benzopyrone) in combination with cimetidine can produce objective antitumor responses in some patients with advanced renal cell carcinoma. The purpose of this report is...
10.
Mohler J, Williams B, Thompson I, MARSHALL M
J Cancer Res Clin Oncol
. 1994 Jan;
120 Suppl:S35-8.
PMID: 8132702
The unavailability of effective treatment for metastatic hormone-refractory and clinically localized but pathologically unfavorable prostatic carcinoma warrants trial of new and promising treatments. Preliminary studies in patients with metastatic disease...